|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2011-5-17
|
|
pubmed:abstractText |
There are no validated methods of early detection of cardiotoxicity from trastuzumab (T) following anthracycline-based chemotherapy. Currently changes in left ventricular ejection fraction (LVEF) are assessed but this approach has limited sensitivity and specificity. Within a prospective feasibility study of dose-dense (dd) doxorubicin and cyclophosphamide (AC) ? weekly paclitaxel (P) with T and lapatinib (L), we included a preplanned analysis of correlative cardiac Troponin I (cTnI) and C-reactive protein (CRP) as early biomarkers of cardiotoxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Biomarkers, Pharmacological,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Troponin I,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/lapatinib,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AbbruzziAlysonA,
pubmed-author:ComeStevenS,
pubmed-author:DangChau TCT,
pubmed-author:DicklerMauraM,
pubmed-author:FLAGGLLJr,
pubmed-author:FleisherMartinM,
pubmed-author:HudisClifford ACA,
pubmed-author:LehmanRobertR,
pubmed-author:LinNancyN,
pubmed-author:McArthurHeather LHL,
pubmed-author:MorrisPatrick GPG,
pubmed-author:MoyBeverlyB,
pubmed-author:NortonLarryL,
pubmed-author:PatilSujataS,
pubmed-author:SteingartRichardR,
pubmed-author:SugarmanStevenS,
pubmed-author:WinerEricE
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3490-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21372222-Adult,
pubmed-meshheading:21372222-Aged,
pubmed-meshheading:21372222-Antibodies, Monoclonal,
pubmed-meshheading:21372222-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21372222-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21372222-Biomarkers, Pharmacological,
pubmed-meshheading:21372222-Breast Neoplasms,
pubmed-meshheading:21372222-C-Reactive Protein,
pubmed-meshheading:21372222-Carcinoma,
pubmed-meshheading:21372222-Dose-Response Relationship, Drug,
pubmed-meshheading:21372222-Feasibility Studies,
pubmed-meshheading:21372222-Female,
pubmed-meshheading:21372222-Humans,
pubmed-meshheading:21372222-Middle Aged,
pubmed-meshheading:21372222-Quinazolines,
pubmed-meshheading:21372222-Stroke Volume,
pubmed-meshheading:21372222-Troponin I,
pubmed-meshheading:21372222-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
|
|
pubmed:affiliation |
Memorial Sloan-Kettering Cancer Center, New York, NY, USA. morrisp1@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
